Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,108.00    -5.50 (-0.49%)
Bid:
1,108.00
Ask:
1,109.00
Spread: 1.00 (0.09%)
Market Cap: £9.37b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Acquisition

5 Jan 2016 07:00

RNS Number : 7712K
Smith & Nephew Plc
05 January 2016
Β 

Β 

Β 

Β 

Smith & Nephew completes acquisition of surgical robotics business Blue Belt Technologies

Β 

5 January 2016

Β 

Β 

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces it has completed the acquisition of Blue Belt Holdings, Inc. ("Blue Belt Technologies"), securing a leading position in the fast-growing area of orthopaedic robotics-assisted surgery.

Β 

Blue Belt Technologies' Navioβ—Š surgical system currently provides robotics-assistance in unicondylar or partial knee replacement surgery through CT-free navigation software and a unique hand-held, robotic bone-shaping device. Navio and Smith & Nephew's partial knee implant portfolio form a strong combined business from which to accelerate growth in this attractive area of surgery. Additionally, the Group intends to expand the Navio platform into total knee, bi-cruciate retaining knee and revision knee implants, delivering significant further upside.

Β 

Enquiries

Β 

InvestorsIngeborg ØieSmith & Nephew

Β +44 (0) 20 7960 2285

Β 

Financial MediaCharles ReynoldsSmith & Nephew

+44 (0) 20 7401 7646

Β 

Ben Atwell / Matthew ColeFTI Strategic Consulting

Β 

+44 (0) 20 3727 1000

Β 

Trade Media

Joe Metzger

Smith & Nephew

Β 

Β 

+1 (978) 749-1330

Β 

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 14,000 employees and a presence in more than 100 countries. Annual sales in 2014 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

Β 

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

Β 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

Β 

β—ŠTrademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ACQEAKFLEEDKEFF
Date   Source Headline
16th Dec 202411:50 amRNSHolding(s) in Company
12th Dec 20249:53 amRNSHolding(s) in Company
11th Dec 20249:03 amRNSHolding(s) in Company
9th Dec 20243:00 pmRNSDirector/PDMR Shareholding
6th Dec 20247:00 amRNSDirector Share Award vest and sale to cover tax
5th Dec 20243:35 pmRNSHolding(s) in Company
5th Dec 20247:00 amRNSHolding(s) in Company
4th Dec 20248:43 amRNSHolding(s) in Company
2nd Dec 202411:30 amRNSTotal Voting Rights
12th Nov 20247:00 amRNSDirector/PDMR Shareholding
11th Nov 20244:45 pmRNSDirector/PDMR Shareholding
1st Nov 20243:44 pmRNSDirector/PDMR Shareholding
1st Nov 20242:30 pmRNSTotal Voting Rights
31st Oct 20247:00 amRNSSmith+Nephew Third Quarter 2024 Trading Report
24th Oct 20247:00 amRNSSterling Amount of Dividend
16th Oct 20247:00 amRNSNotice of Results
1st Oct 20243:44 pmRNSTotal Voting Rights
27th Sep 202412:23 pmRNSChange to Directors' Role and Responsibilities
24th Sep 20249:00 amRNSDirector/PDMR Shareholding
19th Sep 20243:50 pmRNSDirector/PDMR Shareholding
17th Sep 20242:27 pmRNSDirector/PDMR Shareholding
13th Sep 20243:16 pmRNSDirector/PDMR Shareholding
2nd Sep 20244:11 pmRNSTotal Voting Rights
30th Aug 202410:38 amRNSDirector/PDMR Shareholding
16th Aug 20249:32 amRNSDirector/PDMR Shareholding
14th Aug 20241:14 pmRNSDirector/PDMR Shareholding
14th Aug 202411:05 amRNSDirector/PDMR Shareholding
12th Aug 20247:00 amRNSAdoption of Remuneration Policy and RSP
7th Aug 20247:00 amRNSDirector/PDMR Shareholding
5th Aug 202412:08 pmRNSBlock listing Interim Review
1st Aug 202411:09 amRNSTotal Voting Rights
1st Aug 20247:00 amRNSHalf-year Report
12th Jul 20247:00 amRNSDirector/PDMR Shareholding
9th Jul 20247:00 amRNSNotice of Results
4th Jul 20247:00 amRNSTR1: Notification of Major Holdings
3rd Jul 20247:00 amRNSTR1: Notification of Major Holdings
1st Jul 20244:22 pmRNSTotal Voting Rights
3rd Jun 20242:03 pmRNSTotal Voting Rights
30th May 20246:17 pmRNSDirector/PDMR Shareholding
24th May 20244:37 pmRNSDirector/PDMR Shareholding
22nd May 20244:23 pmRNSDirector/PDMR Shareholding
21st May 20249:52 amRNSDirector/PDMR Shareholding
9th May 20247:00 amRNSDividend Declaration
8th May 20247:00 amRNSDirectorate Change
1st May 20244:47 pmRNSResult of AGM
1st May 20241:35 pmRNSTotal Voting Rights
1st May 20247:00 amRNSQ1 2024 Trading Update
23rd Apr 20249:46 amRNSTiming of Smith+Nephew Q1 2024 Trading Report
2nd Apr 20241:43 pmRNSTotal Voting Rights
2nd Apr 20241:19 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.